CCL: an effective form of visual rehabilitation

Article

UVA induced collagen crosslinking (CCL) followed by surface excimer ablation shows promise as a safe and effective technique for visual rehabilitation in eyes with keratoconus or postLASIK ectasia, said A. John Kanellopoulos, MD, speaking at the 2006 AAO meeting in Las Vegas.

UVA induced collagen crosslinking (CCL) followed by surface excimer ablation shows promise as a safe and effective technique for visual rehabilitation in eyes with keratoconus or postLASIK ectasia, said A. John Kanellopoulos, MD, speaking at the 2006 AAO meeting in Las Vegas.

Dr Kanellopoulos, associate professor of ophthalmology, New York University Medical College, and medical director, Laservision-gr. Institute, Athens, Greece, presented results from a case series of 27 eyes that were treated with UVA induced CCL. After a delay of at least 6 months, a topography-guided, limited PRK was performed using the WaveLight system in 14 of those eyes in order to normalize the cornea and improve vision.

At 6 months after the UVA CCL procedure, the keratoconus and ectasia appeared stabilized. In 22 eyes, there was a reduction of the steep K by at least 2 D, and 22 eyes also showed a decrease of at least 2.4 D in spherical equivalent (SE). Endothelial cell count increased paradoxically, and in patients with an untreated, fellow affected eye, there was worsening of the corneal pathology.

Among the eyes that underwent PRK after UVA CCL, mean UCVA improved from 20/400 to 20/60 and mean BCVA improved from 20/100 to 20/40. SE was reduced by 6.4 D, steep K increased from 54 D to 47 D, and the pachymetry changed from 450 to 397 microns. Two eyes developed mild haze.

"In my practice, I see no reason not to treat keratoconus eyes with UVA CCL, but I caution clinicians that this modality has not been investigated in an FDA trial and is not FDA approved," Dr Kanellopoulos said. "My experience also shows PRK after UVA CCL provides very gratifying visual rehabilitation".

"However, I currently perform PRK first followed by UVA CCL at the same visit because I believe that approach will offer a window for retreatment if necessary," he said. "Now, longer follow-up and additional studies are needed".

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.